17 completed, 9 terminated, 7 recruiting, 1 active not recruiting. 27 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 27 | Completed 13, Recruiting 7, Terminated 7 |
| Phase 2 | 11 | Completed 4, Terminated 4, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
Follow Xencor, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of XmAb412 in Healthy Participants XmAb412 Monoclonal Bispecific Antibody, Placebo - Not Applicable - Healthy Adult Participants | Phase 1 | Recruiting | Xencor, Inc. | 128 | 2026-07-13 | 2026-08-03 |
| Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors XmAb541, XmAb808 - Ovarian Cancer | Phase 1 | Recruiting | Xencor, Inc. | 90 | 2026-06-30 | 2026-08-13 |
| A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases XmAb657 - Healthy, Idiopathic Inflammatory Myopathies | Phase 1 | Recruiting | Xencor, Inc. | 60 | 2026-02-24 | 2026-08-03 |
| A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis Plamotamab - Rheumatoid Arthritis | Phase 1 | Recruiting | Xencor, Inc. | 68 | 2025-10-21 | 2026-08-03 |
| Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis XmAb942, Placebo - Ulcerative Colitis (UC) | Phase 1 / Phase 2 | Recruiting | Xencor, Inc. | 270 | 2024-10-10 | 2026-10-30 |
| Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors XmAb541 - Ovarian Cancer, Endometrial Cancer | Phase 1 | Recruiting | Xencor, Inc. | 282 | 2024-04-04 | 2026-10-09 |
| Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC Vudalimab + Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed - Nonsquamous Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Xencor, Inc. | 28 | 2023-12-27 | 2026-03-13 |
| Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer Abiraterone, Biospecimen Collection, Bone Scan - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 | Terminated | Emory University | 4 | 2023-08-03 | 2025-09-15 |
| A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors XmAb662, Keytruda® (pembrolizumab) - Solid Tumors | Phase 1 | Terminated | Xencor, Inc. | 7 | 2023-07-28 | 2024-08-23 |
| Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) Regorafenib, XmAb20717 - Colorectal Cancer, Colon Cancer | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2023-05-17 | 2024-04-29 | |
| A Study of XmAb23104 in People With Sarcoma XmAb23104 - Sarcoma | Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 6 | 2023-04-06 | 2026-04-13 |
| XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy XmAb22841, XmAb23104 - Metastatic Melanoma, Advanced Melanoma | Phase 1 | Terminated | University of California, San Francisco | 6 | 2023-02-28 | 2025-03-26 |
| Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors XmAb®808, Keytruda® (pembrolizumab) - Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma | Phase 1 | Completed | Xencor, Inc. | 60 | 2022-12-14 | 2025-08-07 |
| Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis XmAb27564, Placebo - Psoriasis, Atopic Dermatitis | Phase 1 | Terminated | Xencor, Inc. | 23 | 2022-10-10 | 2025-12-02 |
| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies vudalimab - Ovarian Cancer, Clear Cell Carcinoma | Phase 2 | Active not recruiting | Xencor, Inc. | 170 | 2022-07-21 | 2025-02-07 |
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma XmAb819 - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | Xencor, Inc. | 307 | 2022-06-13 | 2026-08-03 |
| Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) Plamotamab, Tafasitamab, Lenalidomide - Diffuse Large-cell B-cell Lymphoma | Phase 2 | Terminated | Xencor, Inc. | 3 | 2022-04-15 | 2024-04-30 |
| XmAb20717 in Advanced Biliary Tract Cancers XmAb20717 - Biliary Tract Cancer | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 27 | 2022-04-11 | 2026-09-21 |
| XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy - Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Completed | Xencor, Inc. | 72 | 2021-10-22 | 2026-05-05 |
| Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer XmAb18087, XmAb18087 ± Pembrolizumab - Merkel Cell Carcinoma, Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Xencor, Inc. | 4 | 2021-05-10 | 2023-04-20 |
Showing 20 of 35. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (5) · Carcinoma, Renal Cell (5) · Colorectal Neoplasms (5) · Endometrial Neoplasms (5) · Prostatic Neoplasms (5) · Carcinoma, Transitional Cell (4) · Melanoma (4) · Ovarian Neoplasms (4) · Small Cell Lung Carcinoma (4) · Squamous Cell Carcinoma of Head and Neck (4) · Triple Negative Breast Neoplasms (4) · Uterine Cervical Neoplasms (4) · Carcinoma, Hepatocellular (3) · Fallopian Tube Neoplasms (3) · Liver Neoplasms (3)
pembrolizumab (4) · Carboplatin (2) · Docetaxel (2) · tafasitamab (2) · Glutamate Carboxypeptidase II (1) · Ipilimumab (1) · Lenalidomide (1) · Magnetic Resonance Spectroscopy (1) · Pemetrexed (1) · Specimen Handling (1) · XMAB-2513 (1) · abiraterone (1) · cabazitaxel (1) · enzalutamide (1) · olaparib (1)
United States (31) · Spain (5) · Australia (4) · France (4) · Belgium (3) · United Kingdom (3) · Canada (2) · Georgia (2) · Greece (2) · Moldova (2) · Portugal (2) · Argentina (1) · Brazil (1) · Bulgaria (1) · Chile (1)
Jolene Shorr (3) · Benjamin Thompson, MD, PhD (2) · Ralph Zitnik, MD (2) · Adil Daud, MD (1) · Anas Younes, MD (1) · Bassel Nazha, MD, MPH (1) · Chet Bohac, MD (1) · Chet Bohac, MD, MSc (1) · Chet Bohac, PharmD, MD, MSc (1) · Ciara Kelly, MBBCh BAO (1)
PMID 25301708, PMID 33433743, PMID 37459248, PMID 37647601, PMID 38251576, PMID 39636565, PMID 39990653
P30CA138292 (1)